青少年女性HPV疫苗接种后长期疲劳风险未发现增加证据
荷兰一项回顾性队列研究在初级保健数据库中分析1991-2000年出生女孩,比较HPV疫苗接种前后慢性疲劳综合征(CFS)及疲劳≥6个月、3-6个月的发病率,并采用自身对照病例系列分析。结果显示接种前后发病率差异无统计学意义,SCCS分析未发现高风险期疲劳风险升高。
要点
- 接种后CFS、疲劳≥6个月及3-6个月发病率与接种前相比差异无统计学意义。
- SCCS分析16例接种病例,年龄调整RR为0.62(95%CI 0.07-5.49)。
- 青少年女性中疲劳≥6个月和3-6个月较常见,但CFS诊断罕见。
核心结论
- 未发现HPV疫苗接种后长期疲劳或慢性疲劳综合征风险增加的统计学显著证据。
研究设计与样本
- 回顾性队列研究,使用Integrated Primary Care Information数据库,纳入1991-2000年出生女孩,随访2007-2014年,比较接种前后12-16岁女孩发病率,并对同意者进行自身对照病例系列分析。
主要发现
- 队列含69,429名12-16岁女孩,接种前2758人年,接种后57,214人年。
- CFS发病率接种前3.6(95%CI 0.5-25.7)/10,000人年 vs 接种后0.9(0.4-2.1),差异无统计学意义。
- 特定疲劳≥6个月发病率接种前7.3(1.8-29.0) vs 接种后19.4(16.1-23.4)/10,000人年,差异无统计学意义。
- 特定疲劳3-6个月发病率接种前0.0 vs 接种后16.6(13.6-20.3)/10,000人年,差异无统计学意义。
- SCCS分析16例同意接种病例,年龄调整RR为0.62(95%CI 0.07-5.49)。
临床怎么用
- 可为青少年女性HPV疫苗接种后长期疲劳的安全性咨询提供参考,未发现统计学显著风险增加。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In 2013, the Netherlands Pharmacovigilance Center Lareb published an overview of reports of long-lasting fatigue following bivalent HPV-vaccination (2vHPV). After an update of this overview in 2015, concerns regarding the safety of 2vHPV was picked up by the media, which led to further reports of long-lasting fatigue. Therefore, the Dutch National Institute for Public Health and the Environment (RIVM) investigated a possible association between HPV-vaccination and long-term fatigue. METHODS: In this retrospective cohort study conducted in the Integrated Primary Care Information database, we investigated the occurrence of chronic fatigue syndrome (CFS), fatigue ≥6 months and 3-6 months in all girls born in 1991-2000 during the follow-up period January 1st 2007-December 31st 2014 (2007-2008 pre-vaccination and 2009-2014 post-vaccination). Patients with certain fatigue ≥6 m were asked for consent to link their primary care information with vaccination data. Incidence rates per 10,000 person years (PY) for 12-16-year-old girls were compared between pre- and post-HPV-vaccine era. A self-controlled case series (SCCS) analysis was performed using consenting vaccinated cases. A primary high-risk period of 12 months after each dose was defined. RESULTS: The cohort consisted of 69,429 12-16-year-old girls accounting for 2758 PY pre-vaccination and 57,214 PY post-vaccination. Differences between pre- and post-vaccination incidences (CFS: 3.6 (95% CI 0.5-25.7)/10,000 PY and 0.9 (0.4-2.1); certain fatigue ≥6 m: 7.3 (1.8-29.0) and 19.4 (16.1-23.4); certain fatigue 3-6 m: 0.0 and 16.6 (13.6-20.3), respectively) were not statistically significant. SCCS analyses in 16 consenting vaccinated cases resulted in an age-adjusted RR of 0.62 (95%CI 0.07-5.49). CONCLUSIONS: Fatigue ≥6 m and 3-6 m was frequently found among adolescent girls, but CFS was rarely diagnosed. No statistically significant increased incidence rates were found post-vaccination compared to similar age groups of girls pre-vaccination. The SCCS analysis included a low number of cases but revealed no elevated risk of certain fatigue ≥6 m in the high-risk period.
引用
- Schurink-Van't Klooster TM, Kemmeren JM, van der Maas NAT, et al. No evidence found for an increased risk of long-term fatigue following human papillomavirus vaccination of adolescent girls. Vaccine. 2018. PMID: 30262246. doi:10.1016/j.vaccine.2018.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。